Oramed Pharmaceuticals (ORMP) Competitors $2.16 -0.08 (-3.57%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.16 +0.00 (+0.23%) As of 07/25/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. TNXP, FHTX, CADL, AURA, ABEO, PRTA, ATXS, ALT, AMRN, and PVLAShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), Abeona Therapeutics (ABEO), Prothena (PRTA), Astria Therapeutics (ATXS), Altimmune (ALT), Amarin (AMRN), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors Tonix Pharmaceuticals Foghorn Therapeutics Candel Therapeutics Aura Biosciences Abeona Therapeutics Prothena Astria Therapeutics Altimmune Amarin Palvella Therapeutics Tonix Pharmaceuticals (NASDAQ:TNXP) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Is TNXP or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Oramed Pharmaceuticals' return on equity of -11.34% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Oramed Pharmaceuticals N/A -11.34%-10.73% Which has more volatility & risk, TNXP or ORMP? Tonix Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Do analysts prefer TNXP or ORMP? Tonix Pharmaceuticals presently has a consensus price target of $70.00, suggesting a potential upside of 40.79%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to TNXP or ORMP? In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Tonix Pharmaceuticals and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.24 beat Tonix Pharmaceuticals' score of 0.62 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Tonix Pharmaceuticals Positive Oramed Pharmaceuticals Positive Do insiders and institutionals hold more shares of TNXP or ORMP? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, TNXP or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Tonix Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M36.27-$130.04M-$1.96 thousand-0.03Oramed Pharmaceuticals$1.34M65.85-$19.06M-$0.44-4.91 SummaryTonix Pharmaceuticals and Oramed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.49M$10.55B$5.70B$9.51BDividend YieldN/A2.00%4.69%4.01%P/E Ratio-4.9117.0728.1020.06Price / Sales65.8529.18429.1688.51Price / CashN/A23.0336.2258.56Price / Book0.603.698.665.87Net Income-$19.06M$234.77M$3.25B$258.55M7 Day Performance1.89%6.32%4.22%3.73%1 Month Performance-0.46%7.94%10.51%11.75%1 Year Performance-16.92%-13.57%34.39%18.02% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.0765 of 5 stars$2.16-3.6%N/A-15.0%$91.49M$1.34M-4.9110News CoverageTNXPTonix Pharmaceuticals2.5878 of 5 stars$45.10-3.9%$585.00+1,197.1%-14.2%$345.13M$10.09M0.0050FHTXFoghorn Therapeutics2.1377 of 5 stars$6.10-0.5%$12.13+98.8%-5.1%$341.70M$22.60M-4.49120News CoveragePositive NewsCADLCandel Therapeutics2.0853 of 5 stars$6.57-2.5%$22.00+234.9%+7.8%$337.69M$120K-4.9060AURAAura Biosciences2.4228 of 5 stars$6.77+0.9%$22.00+225.0%-29.6%$337.30MN/A-3.5650News CoveragePositive NewsABEOAbeona Therapeutics3.7455 of 5 stars$6.75+2.4%$19.25+185.2%+29.8%$337.12M$3.50M-5.3190PRTAProthena3.8419 of 5 stars$6.29+0.5%$31.50+400.8%-73.1%$336.96M$135.16M-3.02130Positive NewsATXSAstria Therapeutics1.9173 of 5 stars$6.26+4.9%$30.00+379.2%-44.4%$336.91MN/A-3.3530Positive NewsALTAltimmune2.0814 of 5 stars$4.05-0.7%$18.20+349.4%-39.0%$330.92M$20K-3.2150AMRNAmarin0.2442 of 5 stars$15.55-1.7%$12.00-22.8%-2.7%$327.58M$228.61M-4.27360Upcoming EarningsPVLAPalvella Therapeutics1.4235 of 5 stars$31.00+5.0%$47.50+53.2%N/A$326.25M$42.81M-2.56N/A Related Companies and Tools Related Companies Tonix Pharmaceuticals Competitors Foghorn Therapeutics Competitors Candel Therapeutics Competitors Aura Biosciences Competitors Abeona Therapeutics Competitors Prothena Competitors Astria Therapeutics Competitors Altimmune Competitors Amarin Competitors Palvella Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
